Tuesday - June 2, 2026
Imfinzi Plus Imjudo Combined With Lenvatinib and TACE Reduced the Risk of Disease Progression or Death by 30% in Embolization-Eligible Unresectable Liver Cancer in EMERALD-3 Phase III Trial
June 02, 2026
WILMINGTON, Delaware, June 2 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

IMFINZI(R) (durvalumab) plus IMJUDO(R) (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

Positive overall survival trend in favor of STRIDE regimen with lenvatinib and TACE

-

Posit . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products